Khan Nadia H, Rouphael Nadine G, Baden Lindsey R, Graciaa Daniel S
College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14850, USA.
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Vaccines (Basel). 2022 Jan 27;10(2):201. doi: 10.3390/vaccines10020201.
While the development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines was rapid, time to development and implementation challenges remain that may impact the response to future pandemics. Trained immunity via bacille Calmette-Guerin (BCG) vaccination (an antigen agnostic strategy) offers a potential intervention against future novel pathogens via an existing, safe, and widely distributed vaccine to protect vulnerable populations and preserve health system capacity while targeted vaccines are developed and implemented.
虽然严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗的研发速度很快,但研发和实施过程中仍存在挑战,这些挑战可能会影响对未来大流行的应对。通过卡介苗(BCG)接种产生的训练免疫(一种与抗原无关的策略)提供了一种潜在的干预措施,可通过现有的、安全且广泛分布的疫苗来应对未来的新型病原体,以保护弱势群体并在研发和实施针对性疫苗时保持卫生系统的能力。